Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

This multicenter phase 1/2 trial investigated the combination of bendamustine, lenalidomide, and dexamethasone in repeating 4-week cycles as treatment for relapsed refractory multiple myeloma (MM). Phase 1 established maximum tolerated dose (MTD). Phase 2 assessed overall response rate at the MTD. S...

Full description

Saved in:
Bibliographic Details
Main Authors: Lentzsch, Suzanne, O'Sullivan, Amy, Kennedy, Ryan C., Abbas, Mohammad, Dai, Lijun, Pregja, Silvana Lalo, Burt, Steve, Boyiadzis, Michael, Roodman, G. David, Mapara, Markus Y., Agha, Mounzer, Waas, John, Shuai, Yongli, Normolle, Daniel, Zonder, Jeffrey A.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2012
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3392072/
https://ncbi.nlm.nih.gov/pubmed/22451423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-395715
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items